Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

Abstract: Systems and/or methods for producing free elements, systems and/or methods for producing element storage/generation vessel assemblies, element storage/generation vessel assemblies, system and/or methods for purifying elements and providing a progeny generating assemblies are provided.

Abstract: Methods for separating Ra from Pb, Bi, and Th are provided, the methods can include: providing a first mixture comprising Ra, Pb, Bi, and/or Th; providing a system that can include: a first vessel housing a first media; a second vessel in fluid communication with the first vessel, the second vessel housing a second media; and a third vessel in fluid communication with the second vessel, the third vessel housing a third media; and exposing the first mixture to the first media within the first vessel then, through the fluid communication, exposing the first remainder to the second media in the second vessel, then, through fluid communication, exposing the next remainder to the third media in the third vessel, the exposing separating the Th and Bi from the Ra and Pb, and the Ra from the Pb. Methods for separating Ra from being associated with a media are also provided. The methods can include: exposing the Ra and media to a chelating agent to form a mixture comprising the Ra complexed with the chelating agent.

Abstract: Methods for the near real-time detection of airborne analytes using imprinted micelles and electrochemical cells are described. The methods demonstrate selectivity to the imprinted micelles over others that are of similar size and configuration and are compatible with airborne aerosol sampling techniques. The detection method can be used to monitor and detect any airborne analyte, including pathogens (such as SARS-CoV-2), toxins, proteins, organic molecules, inorganic particles, chemicals, explosive particles, and environmental pollutants.

Abstract: A new column-based purification system and approach are described for rapid separation and purification of the alpha-emitting therapeutic radioisotope 211At from dissolved cyclotron targets that provide highly reproducible product results with excellent 211At species distributions and high antibody labeling yields compared with prior art manual extraction results of the prior art that can be expected to enable enhanced production of purified 211At isotope products suitable for therapeutic medical applications such as treatment of cancer in human patients.

Abstract: The present application provides a Chondroitinase ABC (ChABC) mutants. ChABC stimulates axonal regeneration by degrading the inhibitory chondroitin sulfate (CS) and dermatan sulfate (DS) proteoglycans in the glial scar that forms after traumatic injuries to the central nervous system (CNS). However, the therapeutic utility of this potent, fragile protein is severely limited by rapid aggregation at physiological temperature. To overcome this limitation, the ChABC mutants were engineered to at least 15 point mutations in domain 2 of the wild-type ChABC and/or at least 5 point mutations in domain 3 of the wild-type enzyme. These mutants exhibit improved stability over wild-type ChABC. The present application further provides method and compositions comprising the mutant ChABC for treating conditions associated with excess proteoglycan formation or conditions for which treatment is benefitted by degradation of proteoglycans, including CNS injuries, scarring and cancer.

Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

Abstract: An isotope production system, emanation generator, and process are disclosed for production of high-purity radioisotopes. In one implementation example, high-purity Pb-212 and/or Bi-212 isotopes are produced suitable for therapeutic applications. In one embodiment the process includes transporting gaseous radon-220 from a radium-224 bearing generator which provides gas-phase separation of the Rn-220 from the Ra-224 in the generator. Subsequent decay of the captured Rn-220 accumulates high-purity Pb-212 and/or Bi-212 isotopes suitable for direct therapeutic applications. Other high-purity product isotopes may also be prepared.

Abstract: An isotope production system, emanation generator, and process are disclosed for production of high-purity radioisotopes. In one implementation example, high-purity Pb-212 and/or Bi-212 isotopes are produced suitable for therapeutic applications. In one embodiment the process includes transporting gaseous radon-220 from a radium-224 bearing generator which provides gas-phase separation of the Rn-220 from the Ra-224 in the generator. Subsequent decay of the captured Rn-220 accumulates high-purity Pb-212 and/or Bi-212 isotopes suitable for direct therapeutic applications. Other high-purity product isotopes may also be prepared.

Abstract: A new column-based purification system and approach are described for rapid separation and purification of the alpha-emitting therapeutic radioisotope 211At from dissolved cyclotron targets that provide highly reproducible product results with excellent 211At species distributions and high antibody labeling yields compared with prior art manual extraction results of the prior art that can be expected to enable enhanced production of purified 211At isotope products suitable for therapeutic medical applications such as treatment of cancer in human patients.

Abstract: A new column-based purification system and approach are described for rapid separation and purification of the alpha-emitting therapeutic radioisotope 211At from dissolved cyclotron targets that provide highly reproducible product results with excellent 211At species distributions and high antibody labeling yields compared with prior art manual extraction results of the prior art that can be expected to enable enhanced production of purified 211At isotope products suitable for therapeutic medical applications such as treatment of cancer in human patients.

Abstract: Methods for purifying 89Zr are provided, 89Zr compositions are provided, isotope compositions are provided that can include: a radio isotope and a nanoparticle, and methods for radio labeling monoclonal antibodies are provided.

Abstract: Methods for purifying 89Zr are provided, 89Zr compositions are provided, isotope compositions are provided that can include: a radio isotope and a nanoparticle, and methods for radio labeling monoclonal antibodies are provided.

Abstract: Systems and methods for separating Y and Sr are provided. The systems and methods provide combinations of solutions, vessels, and/or media that can provide Y solutions of industrially beneficial concentration.

Abstract: Systems and/or methods for producing free elements, systems and/or methods for producing element storage/generation vessel assemblies, element storage/generation vessel assemblies, system and/or methods for purifying elements and providing a progeny generating assemblies are provided.

Abstract: Systems for separating Ra from a mixture comprising at least Ra, Pb, Bi, and Th are provided. The systems can include: a first vessel housing a first media and Th or Bi; a second vessel in fluid communication with the first vessel, the second vessel housing a second media and Pb; and a third vessel in fluid communication with the second vessel, the third vessel housing a third media and Ra, wherein at least one of the first, second, or third medias are different from the other media.

Abstract: A cam washer for a vehicle suspension system includes a point of rotation about which the washer is configured to rotate, and an outer surface profile where any point along the outer surface profile is configured to provide a friction angle less than a predetermined value to prevent the cam washer bolt from rotating under a load acting on the outer surface profile, the outer surface profile being a function of: i) a shortest distance from the point of rotation to the outer surface profile, ii) a longest distance from the point of rotation to the outer surface profile, iii) a position angle of the outer surface profile, and iv) a coefficient of friction of a material of the washer.

Abstract: Embodiments relate to a cerium-containing nano-coating composition, the composition including an amorphous matrix including one or more of cerium oxide, cerium hydroxide, and cerium phosphate; and crystalline regions including one or more of crystalline cerium oxide, crystalline cerium hydroxide, and crystalline cerium phosphate. The diameter of each crystalline region is less than about 50 nanometers.

Abstract: A cam washer for a vehicle suspension system includes a point of rotation about which the washer is configured to rotate, and an outer surface profile where any point along the outer surface profile is configured to provide a friction angle less than a predetermined value to prevent the cam washer bolt from rotating under a load acting on the outer surface profile, the outer surface profile being a function of: i) a shortest distance from the point of rotation to the outer surface profile, ii) a longest distance from the point of rotation to the outer surface profile, iii) a position angle of the outer surface profile, and iv) a coefficient of friction of a material of the washer.

Abstract: A new column-based purification system and approach are described for rapid separation and purification of the alpha-emitting therapeutic radioisotope 211At from dissolved cyclotron targets that provide highly reproducible product results with excellent 211At species distributions and high antibody labeling yields compared with prior art manual extraction results of the prior art that can be expected to enable enhanced production of purified 211At isotope products suitable for therapeutic medical applications such as treatment of cancer in human patients.